CRISPR: No Sign of Slowing Down
Tipo de material:
TextoSeries ; Cell, 174(5), p.1041, 2018Trabajos contenidos: - Pawluk, A
| Item type | Current library | Collection | Call number | Status | Date due | Barcode | |
|---|---|---|---|---|---|---|---|
Documentos solicitados
|
CICY Documento préstamo interbibliotecario | Ref1 | B-17209 (Browse shelf(Opens below)) | Available |
Just 5 years after its first demonstration as a genome editing tool, CRISPR is pretty much a household name. From its humble beginnings as a way for bacteria to chop up invading viral DNA, CRISPR has taken over our discussions of animal models, high-throughput screens, GMOs, and gene therapy-even biomedical ethics and scientific patent law-all at breakneck speed. While CRISPR is not without its drawbacks, it has major advantages in that it is programmable and applicable to countless organisms, cell types, and research questions. With over 2,500 CRISPR papers published already in 2018, it's easy to wonder whether there is anything truly new left under the sun.
There are no comments on this title.
